Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease Damage: A proof-of-concept study

Rheumatology

Volumn 49, Issue 2, 2010, Pages 373-381

  Arkachaisri, Thaschawee ^a,b   Vilaiyuk, Soamarat ^a   Torok, Kathryn S ^a   Medsger, Thomas A Jr ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Damage index; Global assessment; Localized scleroderma; Outcome measures

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; LOCALIZED SCLERODERMA; LOCALIZED SCLERODERMA SKIN DAMAGE INDEX; MALE; PHYSICIAN GLOBAL ASSESSMENT OF DISEASE DAMAGE; PIGMENT DISORDER; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RHEUMATOLOGY; SCHOOL CHILD; SCORING SYSTEM; SKIN ATROPHY;

EID: 77950413672     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep361     Document Type: Article

References (23)

1. Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998;20:242-5.
2. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997;24:73-80.
3. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol 2008;35:650-7.
4. Arkachaisri T, Vilaiyuk S, Li SC et al. The Localized Scleroderma Skin Severity Index (LoSSI) and Physician Global Assessment of Disease Activity: a work-inprogress toward the development of localizedscleroderma outcome measures. J Rheumatol 2009; (in press).
5. Marzano AV, Menni S, Parodi A et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003;13: 171-6.
6. Zulian F, Vallongo C, Woo P et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005;52:2873-81.
7. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995;70:1068-76.
8. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:942-9.
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
10. DeVellis RF. Scale development: theory and applications. In: Bickman L, Rog DJ, eds. Thousand Oaks: Sage Publication, Inc., 2003.
11. Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health 2007;30:459-67.
12. Carmines EG, Zeller RA. Reliability and validity assessment. In: Lewis-Beck MS, ed. Thousand Oaks: Sage Publications, Inc., 1979.
13. Rider LG, Feldman BM, Perez MD et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997;40:1976-83.
14. Polit DF, Beck CT. The content validity index: are you sure you know what's being reported? Critique and recommendations. Res Nurs Health 2006;29:489-97.
15. Trozak DJ, Tennenhouse DJ, Russell JJ. Dermatology skills for primary care: an illustrated guide. Totowa, NJ: Humana Press, 2006.
16. Buechner SA, Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol 1994;30:441-6.
17. Bendeck SE, Jacobe HT. Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the use of radiologic techniques to assess skin disease. Dermatol Ther 2007;20:86-92.
18. Li SC, Liebling MS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology 2007;46:1316-9.
19. Charman CR, Venn AJ, Williams HC. Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 1999;140:109-11.
20. Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996;135:509-15.
21. Gaines E, Werth VP. Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 2008;300:3-9.
22. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991;124:565-70.
23. Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-94.